
What is Claimed is:

1. A sodium salt of a compound of formula AA



AA


or a hydrate thereof.

2. A crystal form of the sodium salt of a compound or a hydrate according to claim 1 having one or more physical properties selected from the group consisting of (i) and (ii):
(i) having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern; and
(ii) having characteristic infrared absorption spectra at 1641cm^{-1} ± 2cm^{-1}, 1536cm^{-1} ± 2cm^{-1}, 1503cm^{-1} ± 2cm^{-1} and 1424cm^{-1} ± 2cm^{-1}.

3. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 19.2° ± 0.2° and 21.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.


4. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having characteristic diffraction peaks at 6.4° ± 0.2°, 9.2° ± 0.2°, 13.8° ± 0.2°, 14.6° ± 0.2°, 15.2° ± 0.2°, 17.6° ± 0.2°, 19.2° ± 0.2°, 21.8° ± 0.2°, 24.1° ± 0.2° and 28.7° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.

5. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having one or more spectra selected from the group consisting of (a) to (c):
(a) X-ray powder diffraction pattern substantially as shown in Figure 1 ~~below~~;




~~Fig. 1~~

(b) Infrared absorption spectra substantially as shown in Figure 2 ~~below~~; and



~~Fig. 2~~

(c) Solid state ^{13}C-NMR spectra substantially as shown in Figure 3 ~~below~~.



~~Fig. 3~~


6. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having one or more physical properties selected from the group consisting of (iii) and (iv):
(iii) having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°, and 22.8° ± 0.2°degrees two-theta in an X-ray powder diffraction pattern; and
(iv) having characteristic infrared absorption spectra at 1637cm^{-1} ± 2cm^{-1}, 1536cm^{-1} ± 2cm^{-1}, 1501cm^{-1} ± 2cm^{-1} and 1422cm^{-1} ± 2cm^{-1}.

7. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 16.0° ± 0.2°and 22.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.

8. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having characteristic diffraction peaks at 8.0° ± 0.2°, 9.3° ± 0.2°, 11.3° ± 0.2°, 15.4° ± 0.2°, 16.0° ± 0.2°, 18.7° ± 0.2°, 19.1° ± 0.2°, 19.8° ± 0.2°, 22.8° ± 0.2° and 26.8° ± 0.2° degrees two-theta in an X-ray powder diffraction pattern.

9. A crystal form of the sodium salt of a compound or hydrate according to claim 1 having one or more spectra selected from the group consisting of (d) and (e):


(d) X-ray powder diffraction pattern substantially as shown in Figure 4 ~~below~~;



~~Fig. 4~~

and

(e) Infrared absorption spectra substantially as shown in Figure 5 ~~below~~.



~~Fig. 5~~

10. A pharmaceutical composition comprising a crystal form as defined in any one of the claims 2 to 9.